Douglas Lane & Associates LLC Has $39.39 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Douglas Lane & Associates LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 1.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,787 shares of the life sciences company's stock after acquiring an additional 4,442 shares during the period. Douglas Lane & Associates LLC owned 0.19% of Illumina worth $39,392,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Empowered Funds LLC raised its stake in Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company's stock valued at $516,000 after purchasing an additional 66 shares during the last quarter. Caprock Group LLC increased its holdings in shares of Illumina by 3.0% during the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company's stock worth $376,000 after purchasing an additional 83 shares during the period. Integrated Advisors Network LLC raised its position in shares of Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company's stock valued at $585,000 after buying an additional 90 shares during the last quarter. Moors & Cabot Inc. lifted its stake in shares of Illumina by 1.7% in the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company's stock valued at $759,000 after buying an additional 95 shares during the period. Finally, Carson Advisory Inc. grew its position in Illumina by 3.8% during the third quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company's stock worth $360,000 after buying an additional 102 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Price Performance

Shares of ILMN stock traded up $0.60 during trading hours on Wednesday, reaching $139.68. 1,342,769 shares of the company were exchanged, compared to its average volume of 1,406,074. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock's fifty day moving average is $141.62 and its two-hundred day moving average is $131.98. The company has a market cap of $22.15 billion, a price-to-earnings ratio of -14.02 and a beta of 1.11.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.33 EPS. Sell-side analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the subject of a number of research reports. Hsbc Global Res upgraded Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. UBS Group raised their target price on Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. TD Cowen lifted their price target on shares of Illumina from $166.00 to $177.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Stephens increased their price objective on shares of Illumina from $170.00 to $184.00 and gave the company an "overweight" rating in a research note on Tuesday, November 12th. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $156.00 target price on shares of Illumina in a research report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $165.95.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.